The growing need and opportunity to advance biopharma's go-to-market operations has led a biotech veteran to create a medical affairs-focused firm. Richard Ho, a former long-time medical affairs director at Genentech, has created Rype Health, as founder and managing partner. The promise of Rype Health is to disrupt the medical affairs space within the industry by applying a systems approach to optimize what has traditionally been a very fragmented and inefficient business model.
Ho takes deep biopharma experience that began 15 years ago with Astrazeneca, that included field medical, US and Global medical affairs roles. He later helped to build a medical strategy consulting division at healthcare agency Cline Davis & Mann. He followed that with an 8 year run at Genentech in various medical affairs roles at the product, portfolio and functional team levels, and more recently led medical strategy and operations at Ultragenyx.